DEFA14A: Royalty Pharma Executives Discuss Internalization, Pipeline, and Growth Strategy at TD Cowen Healthcare Conference

Royalty Pharma executives discussed the recent internalization of its manager, the company's growth prospects, and its pipeline of royalty assets at the TD Cowen Healthcare Conference.

Summary

• Royalty Pharma executives Terrance Coyne and Marshall Urist participated in a conference call with TD Cowen to discuss the company's recent internalization of its manager and its future prospects.
• The internalization is expected to result in cost savings of over $100 million in 2026, growing to over $175 million by 2030.
• Executives believe the internalization simplifies the company's structure and improves alignment with shareholders.
• Royalty Pharma is focused on continued execution, smart capital allocation, and returning capital to shareholders through share buybacks.
• The company has a diversified portfolio of in-market products and an exciting pipeline of unapproved products.
• Key pipeline assets include Roche's brain shuttle product for Alzheimer's disease, Cytokinetics' Aficamten, and Novartis' and Amgen's Lp(a) programs.
• Tremfya and Cobenfy are performing well, with significant growth potential.
• Royalty Pharma is monitoring the impact of the Inflation Reduction Act (IRA) on its portfolio.
• The company actively sources deals from academia, foundations, and biotech companies.
• Royalty Pharma does not have specific targets for therapeutic categories but focuses on the best assets with the biggest impact on patients and long-term market opportunity.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Royalty Pharma, highlighting the benefits of the internalization, the strength of its portfolio and pipeline, and the company's growth prospects. The management's comments are optimistic, and the overall tone suggests confidence in the company's future performance.

Positives

• Internalization of the manager is expected to generate significant cost savings and improve alignment with shareholders.
• The company has a diversified portfolio of in-market products and a promising pipeline of unapproved products.
• Tremfya and Cobenfy are performing well and have significant growth potential.
• Royalty Pharma has a strong track record of identifying and investing in successful royalty assets.
• The company has a rigorous deal screening process and actively sources deals from various sources.
• The company's large portfolio provides diversification and reduces concentration risk.

Negatives

• The Phase 3 horizon trial for pelacarsen was pushed out slightly from 2025 to 2026.
• The company is monitoring the potential impact of the IRA on its portfolio.
• NIH funding cuts could potentially impact innovation in the biopharma industry over the long term.

Risks

• The company faces regulatory and political risks, including the potential impact of the IRA.
• NIH funding cuts could negatively impact innovation in the biopharma industry.
• Clinical trial results for pipeline assets are uncertain.
• Competition from other companies in the royalty space could impact deal flow and investment opportunities.

Future Outlook

Royalty Pharma expects continued growth in its existing portfolio and pipeline, driven by new product launches and clinical trial readouts. The company is focused on smart capital allocation and returning capital to shareholders.

Management Comments

• Terrance Coyne: 'This was a really big step in the evolution of the company...to combine these two entities.'
• Terrance Coyne: 'The feedback has been really positive. We -obviously, we've been talking to investors after the announcement. And I think people get it.'
• Marshall Urist: 'As much as we have diversity in our end market portfolio, our pipeline has a lot of option value and diversity in it as well.'

Industry Context

Royalty Pharma operates in the pharmaceutical royalty space, providing an alternative investment model to traditional pharmaceutical companies. The company's diversified portfolio and focus on innovative therapies position it well to capitalize on industry growth.

Comparison to Industry Standards

• Royalty Pharma's model is unique, with no direct comparables, but it can be compared to other specialty finance companies or pharmaceutical companies with strong royalty streams.
• The company's ability to own multiple products in the same class differentiates it from traditional pharmaceutical companies with competing clinical development programs.
• Tremfya's potential as a $10 billion-plus opportunity, as projected by J&J's CEO, highlights its potential compared to other drugs in the IBD market.
• The company's investment in Lp(a) programs positions it to benefit from the growing interest in cardiovascular risk reduction, similar to Amgen and Novartis.

Stakeholder Impact

• Shareholders are expected to benefit from the internalization through cost savings, improved alignment, and increased investment returns.
• Patients are expected to benefit from the company's investments in innovative therapies.
• The biopharma industry is expected to benefit from Royalty Pharma's continued support of innovation and drug development.

Next Steps

• Royalty Pharma will file a proxy statement with the SEC regarding the internalization transaction.
• The company will continue to execute its growth strategy, focusing on smart capital allocation and returning capital to shareholders.
• The company will monitor the progress of its pipeline assets and provide updates on clinical trial results.
• The company will continue to actively source deals from academia, foundations, and biotech companies.

Key Dates

Keywords

Royalty Pharma, internalization, pipeline, royalties, pharmaceuticals, investments, healthcare, growth, Tremfya, Cobenfy, Lp(a), IRA